Remove 2021 Remove Clinical Trials Remove Microdosing Remove Safety
article thumbnail

Phase 1 Clinical Trial Data Indicate IGC’s THC-based Investigational New Drug May Reduce Symptoms of Dementia in Alzheimer’s Patients

Cannabis Law Report

(IGC) is excited to present preliminary positive secondary end point findings from its Phase 1 clinical trial for IGC-AD1. The results of the clinical trial have been submitted in the Clinical/Statistical Report (“CSR”) filed with the FDA, and relevant data is also available on Form 8-K filed with the SEC on December 2, 2021.

article thumbnail

Dispatches from Wonderland Miami

Canna Law Blog

Microdose hosted its annual psychedelics conference in Miami last week (appropriately titled “Wonderland”). Some of these companies are already engaged in clinical trials , a key indicator that significant capital and resources are behind entrants into the market.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

The history and science of psychedelics: from acid and shrooms to ketamine and salvia

The Cannigma

What is microdosing? A microdose is a dose that does not elicit a perceivable intoxicating or trip-like effect. At most, a mood boost should be all that is felt, and if any visual or auditory effects are noticeable then the dose is not, by definition, a microdose. Everyone is different.

History 119
article thumbnail

Psychedelic Invest’s 100 Most Influential People in Psychedelics List

Cannabis Law Report

This list is focused on those who have had the largest impact for 2021. . Tim Ferriss is Psychedelics Invest’s number one most influential person for 2021 because of his support through his funding, utilization of his multiple massive social outlets, and his continued balanced message about the efficacy and realities of psychedelic medicines.